Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: DRUG: Akt Inhibitor MK2206|DRUG: Anastrozole|DRUG: Goserelin Acetate|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Neoadjuvant Therapy|OTHER: Pharmacological Study|PROCEDURE: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)